ArticleJournal of cardiovascular electrophysiology2026
Early Bleeding Risk After DOAC Initiation With Concomitant Amiodarone in Older Adults With Atrial Fibrillation.
Article in Journal of cardiovascular electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmiodarone is frequently co-prescribed with direct oral anticoagulants (DOACs) in atrial fibrillation (AF), but its impact on early bleeding risk after DOAC initiation in older adults remains uncertain. We evaluated short-term safety outcomes associated with concomitant amiodarone use at the time of DOAC initiation.
methodsWe performed a retrospective propensity score matched cohort study using the TriNetX US Research Network (2015 to 2025). Adults aged 75 years or older with nonvalvular AF newly initiating a DOAC were included. Exposure was defined as amiodarone prescription or administration within 30 days before or on the DOAC start date. Patients were matched 1:1 on demographics, comorbidities, and baseline cardiovascular medications. Follow-up began 1 day after DOAC initiation and continued for 90 days. Primary outcomes were gastrointestinal (GI) bleeding and intracranial hemorrhage (ICH). Ischemic stroke was a secondary outcome.
resultsAfter matching, 136,806 patients were included (68,403 per cohort), with all standardized mean differences < 0.1. Index-date DOAC exposures were predominantly apixaban (82.7%) and rivaroxaban (16.5%). Concomitant amiodarone use was associated with higher early bleeding risk. GI bleeding occurred in 2.3% vs 1.9% (HR 1.30, 95% CI 1.20 to 1.40), and ICH occurred in 0.4% vs 0.3% (HR 1.28, 95% CI 1.07 to 1.52). There was no significant difference in ischemic stroke (1.3% vs 1.5%; HR 0.91, 95% CI 0.83 to 1.01).
conclusionsAmong adults aged 75 years or older initiating DOAC therapy, concomitant amiodarone exposure was associated with a modest but significant increase in 90-day GI bleeding and ICH without a detectable increase in ischemic stroke. These findings support careful medication review, dose selection, and early bleeding counseling when amiodarone is used with a DOAC in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.